Biotech Leader OmniAb, Inc. to Showcase Cutting-Edge Antibody Discovery Technology In the rapidly evolving landscape of biotechnology, where innovation and precision are paramount, OmniAb, Inc. stands out as a leader in discovery research technology. The company, known for its advanced…
Biotech Leader Takes Helm as Synthekine Advances Phase 2 Cancer Study In the rapidly evolving landscape of biotechnology, where precision and innovation are paramount, Synthekine Inc. is making a strategic move to solidify its position. The company, which specializes in…
Rocket Pharmaceuticals to Present at Major Healthcare Conferences in Boston and Miami In the rapidly evolving landscape of genetic therapies, where precision and innovation are paramount, Rocket Pharmaceuticals, Inc. is making significant strides. The company, a fully integrated, late-stage biotechnology…
Seaport Therapeutics Presents New Meta-Analysis Examining the Impact of Clinical Trial Design Factors on Placebo Response in Generalized Anxiety Disorder Trials Seaport Therapeutics a clinical-stage therapeutics company advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the…
bit.bio Accelerates Global Access to Human Cells with New Pricing Model and Distribution Hub Following a record Q4 in sales volume and the successful closing of $50 million in new funding, bit.bio is leveraging its economies of scale to substantially…
GenSight Biologics Bolsters Regulatory Leadership in US and Europe with Two Senior Appointments GenSight Biologics a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the strategic expansion…
ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia ImmunityBio, Inc. a commercial stage immunotherapy company developing next generation therapies that drive immunological memory…
Bruker Introduces iNTApharma™, a Label‑Free Platform for Nanoparticle Characterization in mRNA Drug and Gene Therapy Development and QC Bruker Corporation today announced the launch of iNTApharma, a label‑free characterization platform that provides single‑particle sensitivity for the quantitative analysis of nanoscale bioparticles in native aqueous…
Bristol Myers Squibb Launches “Change the Target. Change What’s Possible.” Campaign to Address Unmet Needs in Cardiovascular and Thromboembolic Care Bristol Myers Squibb announced today the launch of “Change the Target. Change What’s Possible.” an educational campaign developed in partnership with Johnson…
Real-World Head-to-Head Analysis Reveals 51% Lower Risk of Death in Metastatic Castration-Sensitive Prostate Cancer Patients Treated with ERLEADA® (Apalutamide) Compared to Darolutamide—Without Docetaxel—Over 24 Months Johnson & Johnson today announced new real world head-to-head evidence demonstrating that patients with metastatic castration-sensitive…
Finerenone Recommended in the EU for Heart Failure Patients with LVEF ≥40% Bayer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending finerenone (Kerendia™), a…
DARZALEX FASPRO® quadruplet approved in U.S. for transplant-ineligible newly diagnosed multiple myeloma Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone (D-VRd) for the treatment of…
